^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Colorectal Cancer

Related cancers:
HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
B
Seagen Press Release - 2 weeks - (New B)
ARID1A mutation
Colorectal Cancer
cetuximab
Resistant
:
C3
Nat Commun - 2 weeks - (New C3)
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
KRAS G12C
Colorectal Cancer
cetuximab + MRTX849
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
KRAS G12C
Colorectal Cancer
panitumumab + sotorasib
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
KRAS mutation
Colorectal Cancer
bevacizumab + PCM-075
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
KRAS G12C
Colorectal Cancer
bevacizumab
Resistant
:
C3
ESMO 2022 - 4 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type
Colorectal Cancer
trastuzumab + lapatinib
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
RAS wild-type + BRAF wild-type
Colorectal Cancer
nivolumab + ipilimumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
RAS wild-type
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
C3
ESMO 2022 - 4 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colorectal Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Rectal Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Colorectal Cancer
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Colorectal Cancer
ziv-aflibercept IV
Sensitive
:
A1
No biomarker
Colorectal Cancer
capecitabine
Sensitive
:
A1
EGFR expression
Colorectal Cancer
cetuximab
Sensitive
:
A1
KRAS Q61
Colorectal Cancer
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
ramucirumab
Sensitive
:
A1
KRAS A146
Colorectal Cancer
cetuximab
Resistant
:
A1
No biomarker
Rectal Cancer
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
irinotecan
Sensitive
:
A1
KRAS G13
Colorectal Cancer
cetuximab
Resistant
:
A1
KRAS G12
Colorectal Cancer
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
regorafenib
Sensitive
:
A1
KRAS K117
Colorectal Cancer
cetuximab
Resistant
:
A1
KRAS A59
Colorectal Cancer
cetuximab
Resistant
:
A1
KRAS G12S
Colorectal Cancer
panitumumab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
cetuximab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
cetuximab
Resistant
:
A1